Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
28.45
+0.64 (2.30%)
Dec 19, 2025, 4:00 PM EST - Market closed
Alkermes Revenue
Alkermes had revenue of $390.66M in the quarter ending June 30, 2025, a decrease of -2.12%. This brings the company's revenue in the last twelve months to $1.51B, down -0.17% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.51B
Revenue Growth
-0.17%
P/S Ratio
3.06
Revenue / Employee
$845,188
Employees
1,800
Market Cap
4.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
| Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
| Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
| Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
| Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
| Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
| Dec 31, 2014 | 618.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALKS News
- 8 days ago - Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL - PRNewsWire
- 15 days ago - Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Alkermes to Participate in Two Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Alkermes raises offer for Avadel after Lundbeck bid - Reuters
- 4 weeks ago - Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc - PRNewsWire
- 4 weeks ago - Alkermes plc (ALKS) Shareholder/Analyst Call Transcript - Seeking Alpha
- 5 weeks ago - Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal - Benzinga
- 5 weeks ago - H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal - WSJ